Released Nov 6, 2023, before the open
10-Q filed Nov 6, 2023, 37 days after period end · 0001558370-23-017664
Q3 2023 · 10-Q
Revenue$10.35M$10.35M −27.1% vs Q3 2022−70.5% vs Q2 2023
Net Income-$1.85M-$1.85M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.04-$0.04 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$1,887,000N/M
Operating Cash Flowderived-$6,888,000N/M
Free Cash Flowderived-$7,335,000N/M
Margins · derived
Operating margin-18.2%+3.8 pt vs Q3 2022
Net margin-17.9%+7.2 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $10.35M | $14.18M | $12.05M | $10.79M |
| Net Income | -$1.85M | -$3.57M | -$4.20M | -$4.44M |
| EPS Diluted | -$0.04 | -$0.07 | -$0.09 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR